Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TT125-802
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Pierre Fabre Invest
Deal Size : $39.0 million
Deal Type : Series A Financing
Details : The funding will accelerate the company's lead program, TT125-802, an orally available small molecule CBP/p300 bromodomain inhibitor, into a first-in-human study in patients with solid tumors.
Product Name : TT125-802
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 20, 2023
Lead Product(s) : TT125-802
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Pierre Fabre Invest
Deal Size : $39.0 million
Deal Type : Series A Financing
Reset All
